Literature DB >> 19888926

Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.

James M Stankiewicz1, Bonnie I Glanz, Brian C Healy, Ashish Arora, Mohit Neema, Ralph H B Benedict, Zachary D Guss, Shahamat Tauhid, Guy J Buckle, Maria K Houtchens, Samia J Khoury, Howard L Weiner, Charles R G Guttmann, Rohit Bakshi.   

Abstract

BACKGROUND/
PURPOSE: To assess correlation between brain lesions and clinical status with 1.5T and 3T magnetic resonance imaging (MRI).
METHODS: Brain MRI fluid-attenuated inversion-recovery (FLAIR) sequences were performed in 32 multiple sclerosis (MS) patients. Expanded Disability Status Scale (EDSS) score (mean±standard deviation) was 2±2.0 (range 0-8), disease duration 9.3±8.0 (range .8-29) years.
RESULTS: FLAIR lesion volume (FLLV) at 3T was higher than at 1.5T (P=.01). Correlation between 1.5T FLLV and EDSS score was poor, while 3T FLLV correlated moderately and significantly (rs=.39, P=.03). When controlling for age and depression, correlations between FLLV and cognitive measures were significant at 1.5T for the Judgment of Line Orientation test (JLO) (rs=-.44, P=.05), the Symbol Digit Modalities Test (SDMT) (rs=-.49, P=.02), and the California Verbal Learning Test Delayed Free Recall (CVLT DR) (rs=-.44, P=.04). Correlations at 3T were also significant for these tests, but of greater magnitude: JLO (rs=-.70, P=.0005), SDMT (rs=-.73, P=.0001), CVLT DR (rs=-.061, P=.003). Additional significant correlations obtained only at 3T included the 2 second-paced auditory serial addition test (rs=-.55, P=.01), the Brief Visuospatial Memory Test-Delayed Free Recall (rs=-.56, P=.007), and the California Verbal Learning Test Total Recall (rs=-.42, P=.05).
CONCLUSION: MRI at 3T may boost sensitivity and improve validity in MS brain lesion assessment.
Copyright © 2009 by The American Society of Neuroimaging.

Entities:  

Mesh:

Year:  2011        PMID: 19888926      PMCID: PMC3043123          DOI: 10.1111/j.1552-6569.2009.00449.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  46 in total

1.  Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR.

Authors:  R H Lazeron; D W Langdon; M Filippi; J H van Waesberghe; V L Stevenson; J B Boringa; D Origgi; A J Thompson; M Falautano; C H Polman; F Barkhof
Journal:  Mult Scler       Date:  2000-08       Impact factor: 6.312

2.  North American Adult Reading Test: age norms, reliability, and validity.

Authors:  Bob Uttl
Journal:  J Clin Exp Neuropsychol       Date:  2002-12       Impact factor: 2.475

3.  Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis.

Authors:  M Rovaris; M Filippi; L Minicucci; G Iannucci; G Santuccio; F Possa; G Comi
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

4.  Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study.

Authors:  R A Sperling; C R Guttmann; M J Hohol; S K Warfield; M Jakab; M Parente; E L Diamond; K R Daffner; M J Olek; E J Orav; R Kikinis; F A Jolesz; H L Weiner
Journal:  Arch Neurol       Date:  2001-01

Review 5.  Minimal neuropsychological assessment of MS patients: a consensus approach.

Authors:  Ralph H B Benedict; Jill S Fischer; Cate J Archibald; Peter A Arnett; William W Beatty; Julie Bobholz; Gordon J Chelune; John D Fisk; Dawn W Langdon; Lauren Caruso; Fred Foley; Nicholas G LaRocca; Lindsey Vowels; Amy Weinstein; John DeLuca; Stephen M Rao; Frederick Munschauer
Journal:  Clin Neuropsychol       Date:  2002-08       Impact factor: 3.535

6.  Cognitive impairment and structural brain damage in benign multiple sclerosis.

Authors:  M Rovaris; G Riccitelli; E Judica; F Possa; D Caputo; A Ghezzi; A Bertolotto; R Capra; M Falautano; F Mattioli; V Martinelli; G Comi; M Filippi
Journal:  Neurology       Date:  2008-09-24       Impact factor: 9.910

7.  3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis.

Authors:  Mohit Neema; Daniel Goldberg-Zimring; Zachary D Guss; Brian C Healy; Charles R G Guttmann; Maria K Houtchens; Howard L Weiner; Mark A Horsfield; David B Hackney; David C Alsop; Rohit Bakshi
Journal:  Neuroimage       Date:  2009-03-10       Impact factor: 6.556

Review 8.  Depression in multiple sclerosis: review and theoretical proposal.

Authors:  Peter A Arnett; Fiona H Barwick; Joe E Beeney
Journal:  J Int Neuropsychol Soc       Date:  2008-09       Impact factor: 2.892

9.  Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla.

Authors:  Nancy L Sicotte; Rhonda R Voskuhl; Seth Bouvier; Rochelle Klutch; Mark S Cohen; John C Mazziotta
Journal:  Invest Radiol       Date:  2003-07       Impact factor: 6.016

10.  Normal findings on brain fluid-attenuated inversion recovery MR images at 3T.

Authors:  M Neema; Z D Guss; J M Stankiewicz; A Arora; B C Healy; R Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-15       Impact factor: 3.825

View more
  47 in total

1.  Validity of a computerized version of the symbol digit modalities test in multiple sclerosis.

Authors:  Nadine Akbar; Kimia Honarmand; Nancy Kou; Anthony Feinstein
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

2.  High-resolution 3D-constructive interference in steady-state MR imaging and 3D time-of-flight MR angiography in neurovascular compression: a comparison between 3T and 1.5T.

Authors:  M Garcia; R Naraghi; T Zumbrunn; J Rösch; P Hastreiter; A Dörfler
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-08       Impact factor: 3.825

3.  Combining atlas-based parcellation of regional brain data acquired across scanners at 1.5 T and 3.0 T field strengths.

Authors:  Adolf Pfefferbaum; Torsten Rohlfing; Margaret J Rosenbloom; Edith V Sullivan
Journal:  Neuroimage       Date:  2012-01-26       Impact factor: 6.556

Review 4.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

5.  Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.

Authors:  Z Campbell; D Sahm; K Donohue; J Jamison; M Davis; C Pellicano; S Auh; J Ohayon; J A Frank; N Richert; F Bagnato
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

Review 6.  MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.

Authors:  M Essig; N Anzalone; S E Combs; À Dörfler; S-K Lee; P Picozzi; A Rovira; M Weller; M Law
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-20       Impact factor: 3.825

Review 7.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

8.  The role of education in a vascular pathway to episodic memory: brain maintenance or cognitive reserve?

Authors:  Laura B Zahodne; Elizabeth Rose Mayeda; Timothy J Hohman; Evan Fletcher; Annie M Racine; Brandon Gavett; Jennifer J Manly; Nicole Schupf; Richard Mayeux; Adam M Brickman; Dan Mungas
Journal:  Neurobiol Aging       Date:  2019-08-14       Impact factor: 4.673

9.  Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis.

Authors:  Eric C Klawiter; Antonia Ceccarelli; Ashish Arora; Jonathan Jackson; Sonya Bakshi; Gloria Kim; Jennifer Miller; Shahamat Tauhid; Christian von Gizycki; Rohit Bakshi; Mohit Neema
Journal:  J Neuroimaging       Date:  2014-05-09       Impact factor: 2.486

10.  Variation in longitudinal trajectories of regional brain volumes of healthy men and women (ages 10 to 85 years) measured with atlas-based parcellation of MRI.

Authors:  Adolf Pfefferbaum; Torsten Rohlfing; Margaret J Rosenbloom; Weiwei Chu; Ian M Colrain; Edith V Sullivan
Journal:  Neuroimage       Date:  2012-10-12       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.